Adipose Derived Stem Cells in Facial Fat Grafting

Facial Atrophy Clinical Trial

— SVF  

Official title:

A Phase II Double-blind, Randomized, Study to Assess the Efficacy of Facial Fat Grafts Supplemented With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02526576
• Other study ID #: SSVF0002
• Status: Completed
• Phase: Phase 2
• Start date: August 2015
• Est. completion date: July 2017

Study information

• Verified date: February 2019
• Source: Antria
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase two, randomized, double-blind study is designed to demonstrate the enhanced efficacy of SVF-enriched autologous facial fat grafts, in relation to standard, non-SVF enriched, facial fat grafts by evaluating volumetric retention and contour of the engrafted region over the course of one year.

Description:

Human Adipose Tissue is considered as a new source for Stromal Stem Cells and offers a large therapeutic potential for many rare and common diseases that impacts millions of patients worldwide. The Stromal Vascular Fraction (SVF) of Adipose Tissue is relatively easy to extract with minimally invasive procedures such as elective liposuction in large quantities and therefore may be a cost effective source for cellular therapies in a wide range of medical specialties.

The term "Facial Atrophy" describes the lost of subcutaneous fat within the face and can be a result of the aging process as well as some pathological diseases. It can be corrected via autologous fat transfer but usually the majority of the grafted cells will die after 6-12 months. Several publications demonstrate that the addition of SVF cells to the graft may enhance the graft survival.

This double blind, randomized study aims to demonstrated the efficacy of Antria Cell Preparation Process in autologous facial fat grafting.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Female or Male, Age 18 to 70 years old

2. Subjects that are eligible for liposuction and facial fat grafting procedures for cosmetic purposes and facial atrophy.

3. Subjects must require augmentation to the infra-malar region. Furthermore, facial engraftment to additional, non-study related regions is optional, but not required.

4. Inframalar Atrophy Assessment Scale of 2 to 4

5. Facial volume defect range: 2 to 10 mL

6. Body Mass Index (BMI) between and including 22 and 29

7. Able to understand and provide written and verbal informed consent

8. Fitzpatrick Scale 1 to 6

Exclusion Criteria:

1. Currently taking or have taken None Steroid Anti-inflammatory Drugs (NSAIDs) within last two weeks or corticosteroids within the last six weeks prior to screening

2. Diagnosis of any of the following medical conditions:

• Active malignancy (diagnosed within 5 years), except for treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm (e.g. cervical cancer)

• Active infection

• Type I or Type II Diabetes

• Skin/Bone deformities in the face, including scaring or hyperpigmentation within the graft site.

3. Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, dementia, and/or otherwise considered by the Investigator to be unlikely to complete the study)

4. Subjects with a known drug or alcohol dependence within the past 12 months as judged by the Investigator

5. Dermal fillers or facial reconstruction within the past 24 months, Subjects must also refrain from such procedures during the duration of the study.

6. Subjects with major illnesses involving the renal, hepatic, cardiovascular, and/or nervous systems.

7. Subjects with elevated kidney and/or liver functions

8. Any other disease condition or laboratory results that in the opinion of the investigator may be clinically significant and render the subject inappropriate for the study procedure(s), may alter the accuracy of study results, or increase risk for subjects.

9. Subjects with life-expectancies less than 9 months

10. Subjects with known collagenase allergies

11. Subjects with idiopathic or drug-induced coagulopathy

12. Pregnant females

13. On radiotherapy or chemotherapy agents

14. Taking strong CYP450 inhibitors

15. Subjects with a history of keloids or hypertrophic scar formations

16. Previous treatment with any synthetic fillers in the inframalar area

Related Conditions & MeSH terms

• Atrophy
• Facial Atrophy
• Facies

Intervention

Biological:
• Stromal Vasular Fraction
The stromal vascular fraction obtained from adipose tissue will be added to the graft

Procedure:
• Biopsy
A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months

Locations

Country	Name	City	State
United States	Delmont Surgery Center	Delmont	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Antria

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Volume retention	To demonstrate that SVF administration, in concert with autologous facial fat grafts, is more efficacious, with regards to graft survival, than standard, non-SVF enhanced, autologous facial fat grafts	12 months
Secondary	Number of Participants ith autologous facial fat grafts via laboratory results	To monitor the safety of SVF administration along with autologous facial fat grafts via laboratory results	36 months
Secondary	Changes in the quality of skin	a blinded and independent investigator will assess any changes to the quality of skin	12 months

External Links

•   Site's website
•   Sponsor's website